Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT07340216
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
An Open Label, Phase 1, Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% Administered QD in Pediatric Participants With Scalp and Body Psoriasis
Sponsor: Arcutis Biotherapeutics, Inc.
Conditions
Psoriasis
Interventions
ARQ-154 Foam 0.3%
Updated 1 time since 2026 Last updated: Jan 5, 2026 Started: Dec 15, 2025 Primary completion: Dec 31, 2026 Completion: Feb 28, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07340216, this PHASE1 trial focuses on Psoriasis and remains actively recruiting participants. Sponsored by Arcutis Biotherapeutics, Inc., it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Arcutis Biotherapeutics, Inc.
Data source: Arcutis Biotherapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .